tradingkey.logo
tradingkey.logo
Search

AbbVie, Enanta Pharma rise after US FDA approves pediatric use of hepatitis C drug

ReutersJun 11, 2025 6:07 PM
facebooktwitterlinkedin
View all comments0

Shares of drugmaker AbbVie ABBV.N up 1.5% at $192.40 and biotech company Enanta Pharma ENTA.O up 7.1% to $8.12

AbbVie says the U.S. FDA approves expanded use of its drug, Mavyret, for the treatment of adults and pediatric patients three years and older with hepatitis C virus (HCV) infection

Mavyret was first approved by the FDA in August 2017 to treat hepatitis C virus (HCV) infection in adults

Hepatitis C is a viral infection that causes liver swelling that can lead to serious liver damage

Mavyret was developed through a collaboration between AbbVie and Enanta Pharma

Including session's moves, ABBV up 8.3% and ENTA up 33.2% YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

0/500
Commenting Guidelines
Loading...

Recommended Articles

Tradingkey
KeyAI